Sunbul Murat, Cincin Altug, Mammadov Ceyhun, Mutlu Bulent
Department of Cardiology, Faculty of Medicine, Marmara University, Istanbul, Turkey.
Am J Ther. 2016 May-Jun;23(3):e974-6. doi: 10.1097/MJT.0000000000000129.
Atrial fibrillation (AF) is an important risk factor for cardioembolic stroke. Warfarin is an effective treatment in reducing the risk of cardioembolic stroke in patients with AF. New anticoagulants have been widely using for stroke prophylaxis in patients with nonvalvular AF. Previous studies have suggested that thrombolytic therapy is effective treatment choice in patients with pulmonary embolisms. Warfarin therapy is also effective on prevention or treatment of cardiac thrombus in patients with AF. However, there are no evidence-based data on treatment of cardiac thrombus with new oral anticoagulants in patients with AF. In our case report, we reported an AF patient with cardiac thrombus and pulmonary embolism under dabigatran therapy.
心房颤动(AF)是心源性栓塞性卒中的重要危险因素。华法林是降低AF患者心源性栓塞性卒中风险的有效治疗方法。新型抗凝剂已广泛用于非瓣膜性AF患者的卒中预防。先前的研究表明,溶栓治疗是肺栓塞患者的有效治疗选择。华法林治疗对AF患者心脏血栓的预防或治疗也有效。然而,对于AF患者使用新型口服抗凝剂治疗心脏血栓,尚无循证数据。在我们的病例报告中,我们报道了1例接受达比加群治疗的AF合并心脏血栓和肺栓塞患者。